ReviewFrontiers in cardiovascular medicine2022
Intestinal microbiota: A promising therapeutic target for hypertension.
Review in Frontiers in cardiovascular medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Hypertension-gut microbiota research trends: a bibliometric and visualization analysis (2000-2025).Frontiers in microbiology · 2025Pooled it
- The role of gut microbiome disruption in the development of metabolic dysfunction-associated kidney disease.Acta biochimica Polonica · 2026Review
- Dietary Flavonoids as Cross-System Modulators of Hypertension and Intestinal Permeability.Molecules (Basel, Switzerland) · 2025Review
- The mediating role of inflammatory factors in the association between dietary index for gut microbiota and hypertension.Scientific reports · 2025Article
- Differences in mRNA Expression of Selected Cytochrome P450, Transporters and Nuclear Receptors Among Various Rat Models of Metabolic Syndrome.Basic & clinical pharmacology & toxicology · 2025Article
- Diversity and Composition of Gut Microbiota in Different Developmental Stages of the Tibetan Toad (Animals : an open access journal from MDPI · 2025Article
- An Exploration of the Relationship Between Gut Virome and Cardiovascular Disease: A Comprehensive Review.Reviews in cardiovascular medicine · 2025Review
- Reutericyclin mitigates risperidone-induced suppression of anaerobic energy expenditure.American journal of physiology. Regulatory, integrative and comparative physiology · 2025Article
- Gut Microbiota and Gut-Brain Axis in Hypertension: Implications for Kidney and Cardiovascular Health-A Narrative Review.Nutrients · 2024Review
- Primary Prevention Strategy for Non-Communicable Diseases (NCDs) and Their Risk Factors: The Role of Intestinal Microbiota.Biomedicines · 2024Review
- Effect of Purified Resveratrol Butyrate Ester Monomers against Hypertension after Maternal High-Fructose Intake in Adult Offspring.Nutrients · 2024Article
- Early and late gut microbiota signatures of stroke in high salt-fed stroke-prone spontaneously hypertensive rats.Scientific reports · 2024Article
- Review
- Impact of fundamental components of the Mediterranean diet on the microbiota composition in blood pressure regulation.Journal of translational medicine · 2024Review
- Microbial influence on blood pressure: unraveling the complex relationship for health insights.Microbiome research reports · 2024Article
- The Gut-Organ Axis within the Human Body: Gut Dysbiosis and the Role of Prebiotics.Life (Basel, Switzerland) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hypertension has developed into an escalating serious global public health problem with multiple and unclear pathophysiological mechanisms. Recent studies have identified intestinal microbiota as a key perpetrator of hypertension through a variety of mechanisms. In this review, we highlight the potential roles of the intestinal microbiota and its metabolites in the development of hypertension, as well as the therapeutic potential for targeting intestinal microbiomes. We also shed light on the main limitations and challenges of the current research and suggest directions for future investigations. Finally, we discuss the development of accurate and personalized preventive and therapeutic strategies for hypotension by the modulation of intestinal microbes and metabolites.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.